中国口腔种植学杂志 ›› 2023, Vol. 28 ›› Issue (4): 270-278.DOI: 10.12337/zgkqzzxzz.2023.08.011

• 荟萃分析 • 上一篇    下一篇

自体血小板浓缩物对上颌窦底提升的临床效果影响:基于随机对照试验的Meta分析

赵瑞敏1,2, 龚佳明1,2, 李健学1, 苏琳涵1   

  1. 1解放军联勤保障部队第940医院口腔科,兰州 730050;
    2温州医科大学附属衢州医院(衢州市人民医院)口腔科 324000
  • 收稿日期:2022-12-06 出版日期:2023-08-30 发布日期:2023-09-05
  • 通讯作者: 苏琳涵,Email:14917731@qq.com,电话:0931-8994810
  • 作者简介:赵瑞敏,硕士、医师,研究方向:口腔种植学和循证医学;苏琳涵,硕士、主治医师,研究方向:口腔修复学和口腔种植学
  • 基金资助:
    甘肃省自然科学基金(21JR11RA006)

The autologous platelet concentrates for maxillary sinus floor elevation: a meta-analysis of randomized controlled trials

Zhao Ruimin1,2, Gong Jiaming1,2, Li Jianxue1, Su Linhan1   

  1. 1Department of Stomatology, The 940th Hospital of Joint Logistics Support Force of People's Liberation Army, Lanzhou 730050, China;
    2Department of Stomatology, Quzhou Hospital Affiliated to Wenzhou Medical University (Quzhou people's Hospital), Quzhou 324000, Zhejiang, China
  • Received:2022-12-06 Online:2023-08-30 Published:2023-09-05
  • Contact: Su Linhan, Email: 14917731@qq.com, Tel: 0086-931-8994810
  • Supported by:
    Natural Science Foundation of Gansu Province(21JR11RA006)

摘要: 目的 通过Meta分析方法系统评估在上颌窦底提升(maxillary sinus floor elevation,MSFE)中使用自体血小板浓缩物(autologous platelet concentrates,APC)的疗效。方法 电子检索2000年1月1日至2022年9月30日PubMed、Embase、Web of Science、Cochrane Library、CNKI、万方数据库有关MSFE使用 APC的随机对照试验(randomized controlled trials,RCT)。使用Cochrane Tool评估RCT的偏倚风险,使用RevMan 5.4对数据进行合并分析。结果 共纳入16篇 RCT。Meta分析结果显示,MSFE术后6个月,与上颌窦底单独放置骨增量材料相比,联合 APC的骨增量材料在上颌窦底新骨形成比例、促进材料吸收、提升上颌窦底高度、新骨密度上具有一定优势(P<0.05),而在结缔组织比例、骨-材料接触率、垂直骨吸收、种植体稳定系数上均无统计学差异(P>0.05);术后12个月,联合APC的骨增量材料较单独骨增量材料能获得更佳的窦底提升高度(P<0.05),但后者表现出更稳定的垂直骨高度(P<0.05)。结论 有限证据表明,在MSFE术后中短期随访,联合APC和骨增量材料可取得与骨增量材料移植相比更佳的新骨形成比例、窦底提升高度、新骨密度,且促进材料降解效果,但在结缔组织形成比例、骨-材料接触率、垂直骨吸收和种植体的稳定性上益处不大。仍需要进行更高同质性、更长随访时间的RCT评估APC在MSFE的中短期疗效。

关键词: 自体血小板, 生长因子, 上颌窦底提升, 骨增量, 随机对照试验, Meta分析

Abstract: Objective To systematically evaluate efficacy in the application of autologous platelet concentrates (APC) for maxillary sinus floor elevation (MSFE). Methods The databases of PubMed, Embase, Web of Science, Cochrane Library, CNKI, and Wanfang from 1 January 2000 to 30 September 2022, were electronically searched to identify randomized controlled trials (RCTs) involving MSFE employing APC. The Cochrane Tool was employed to assess the risk of bias. Data were analyzed via RevMan 5.4 software. Results In total 16 RCTs were included. Meta-analyses showed that at 6 months after MSFE, APC presented significant advantages in the proportion of new bone formation, grafted materials absorption, vertical bone augmentation, and bone density except for the proportion of connective tissue, bone-to-bone graft contact rate, vertical bone resorption, and implant stability quotient; At 12 months after MFSE, employing APC mixed grafted materials resulted in a significantly better vertical sinus-bone height than employing bone grafted materials alone, but the latter presented a more stable vertical sinus-bone height. Conclusion Limited evidence implied that during a medium-short follow-up period, employing APC mixed bone grafted materials achieves better performance than sole bone grafted materials in terms of the proportion of new bone formation, sinus-bone height, bone density, and materials degradation, thus, no positive efficacy on the proportion of connective tissue, bone-to-bone graft contact rate and the stability of vertical sinus-bone resorption and implant. Further evidence from RCTs with higher homogeneity and longer follow-up period is needed to evaluate its superiority in MSFE.

Key words: Autologous platelet, Growth factors, Maxillary sinus floor elevation, Bone grafting, Randomized controlled trial, Meta-analysis